A Supreme Court decision handed down last month and previously addressed on this blog may have huge implications not only for the pharmaceutical and medical device industry, but for product liability laws across most manufacturers’ product lines as well.
If you recall, the Supreme Court overwhelmingly ruled in favor of Bristol-Myers Squibb by 8-1 in June. At question was whether plaintiffs from states other than California could join ...
continue reading...
Known as SGLT2 inhibitors for short, sodium glucose co-transporter 2 inhibitors are a class of drugs intended for certain individuals with Type II diabetes. The drugs prevent glucose from being absorbed in the kidneys and reduce glucose in the blood by causing it to be expelled in the urine.
Unfortunately, this relatively new class of drugs has already allegedly caused enough ...
continue reading...
One of the least-known facts in medicine is the amount of leeway a doctor has when it comes to prescribing medicine. They are essentially on their own; the final authority in determining the drugs their patients will take while under their care. So, while the FDA may have approved a drug to treat X condition, biology dictates that it might also have a positive effect on Y condition, and your ...
An item on the blog Pharmalot examines an e-mail suggesting that drugmaker Bristol-Myers Squibb plans to get physicians to lobby state Medicaid programs on the company’s behalf.
According to Pharmalot, the e-mail was sent to the district business manager team with the goal of getting Medicaid programs in Pennsylvania, Delaware and Maryland to place the Onglyza diabetes drug on the state formularies.
Although the blog doesn’t say that the company was doing anything illegal, it does point out that the region business ...
continue reading...An Irish newspaper, the Evening Herald, reports that diabetics in Europe have been warned about a drug used to lower blood sugar, which has been linked to severe side-effects.
According to the report, patients have suffered “serious hypersensitivity reactions” including anaphylactic shock and acute pancreatitis.
Both the Irish Medicines Board and the European Medicines Agency issued warnings about the drug saxagliptin, which has the brand name Onglyza, prescribed for patients with Type 2 diabetes as part of a diet and exercise program ...
continue reading...
